Q-omics provides the consensus-scored MTND2P32 profile across patient tissues and cancer cell-line models. MTND2P32 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, MTND2P32 is differentially expressed in 5, with the highest sampling consensus in KICH. Additionally, MTND2P32 RNA expression shows 5,880 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight THYM, KICH, and ACC as cancer lineages where MTND2P32 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTND2P32 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTND2P32 survival associations across molecular data types. MTND2P32 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTND2P32 RNA expression–survival associations across cancer types. High MTND2P32 expression shows unfavorable associations in THYM and ESCA, but favorable associations in HNSC, KICH, LUAD and BLCA. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for MTND2P32 RNA expression.
This table summarizes MTND2P32 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for MTND2P32. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTND2P32 shows lower tumor expression in ESCA, LUAD and LIHC and higher tumor expression in KICH and STAD. The KICH box plot shows higher MTND2P32 RNA expression in tumor versus normal tissue (log2 FC = +0.074, t-test p = .003).
This table shows molecular features associated with MTND2P32 in patient tissues and cancer cell lines. In patient samples, MTND2P32 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
